Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

From the plant

Δ9-THCHTetrahydrocannabihexol

Hexyl (C6) homologue of Δ9-THC, identified in trace amounts in 2020 without being isolated; activates CB1 in vitro.

Narcotic: generic clause
Level of detail

Harm-reduction warning

No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.

C₂₂H₃₂O₂

CAS 36482-24-3

Family
PhytocannabinoidMinor
Origin
Decarboxylation
Molar mass
328.49 g/mol

Updated on

In plain terms

Tetrahydrocannabihexol is a THC whose side chain has six carbons instead of five. It was detected in 2020 in a medicinal cannabis variety, in amounts so small that it could not be isolated. The few laboratory and mouse studies show THC-like activity; no human study has been published.

Receptors and activity

Target network

CB1AgonistCB1 activation in β-arrestin 2 recruitment, potential higher than that of Δ9-THC; EC50 and Emax values not extracted (Janssens et al. 2024)
  • Activates

The lower the cited value, the closer the target sits to Δ9-THCH: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of Δ9-THCH.

Brain, side view
Body, front view
Blood

CB1CB1 found in 7 regions of the body

  1. Basal gangliadenseMost dense in basal ganglia outflow nuclei1
  2. CerebellumdenseVery dense in the cerebellum1
  3. HippocampusdenseVery high concentrations in the hippocampus2
  4. AmygdaladenseHigh concentrations in the amygdala2
  5. CortexpresentPresent throughout the neocortex2
  6. Adipose tissuepresentExpressed in adipose tissue3
  7. GutpresentColonic epithelium, smooth muscle and plexus4

Map sources

  1. Herkenham M et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A, 1990 (new tab)
  2. Glass M et al. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 1997 (new tab)
  3. Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 2005 (new tab)
  4. Wright K et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology, 2005 (new tab)

Cited values

  1. CB1Agonistno measured value cited

    CB1 activation in β-arrestin 2 recruitment, potential higher than that of Δ9-THC; EC50 and Emax values not extracted (Janssens et al. 2024)

Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Pharmacology

Δ9-Tetrahydrocannabihexol (Δ9-THCH) is the hexyl-chain (C6) homologue of Δ9-THC. Linciano, Citti, Cannazza and colleagues identified it in 2020 in the Italian medicinal cannabis variety FM2, by UHPLC-HRMS and comparison with a synthetic standard, at about 7 µg/g; it was not isolated, its acid being too scarce. The origin of its even-numbered carbon chain remains open. No affinity constant has been published, but in a β-arrestin 2 recruitment assay it showed a higher CB1 activation potential than Δ9-THC (Janssens et al. 2024). In mice, it reduced locomotion and induced catalepsy-like immobility, with a narrower gap between these two effects than for Δ9-THC (Shirakura et al. 2026). In human liver microsomes, it forms hydroxylated and carboxylated metabolites comparable to those of THC (James et al. 2026). No human data have been published. It has been identified in oils sold online in Japan, together with synthesis by-products (Tanaka and Kikura-Hanajiri 2024). In France, it is a controlled narcotic through the generic class of benzo[c]chromene derivatives.

Key sources.

History

Source
Cannabis sativa L.: a constituent present in trace amounts, identified without isolation in the Italian medicinal variety FM2, where its content was estimated at about 7 µg/g, versus 39 mg/g for Δ9-THC (Linciano et al. 2020). No other detection in the plant was found. In oils sold online in Japan in 2022-2023, Δ9-THCH was identified together with by-products attributed to chemical synthesis (Tanaka and Kikura-Hanajiri 2024).

Biosynthetic pathway

Δ9-THCH is the neutral form produced by decarboxylation of its acid, THCHA, present in the plant before decarboxylation (Linciano et al. 2020). The origin of the hexyl chain is not established: homologues with an even number of carbons had until then been assumed to be artefacts of fungal ω-oxidation, and the authors leave the question open while regarding their presence in the plant as certain.

Classification

Family, origin and source verification

Family

Phytocannabinoid › Minor

Presence in the plant

Neutral form: decarboxylation of a plant acid

Chemistry

Type Δ9-THC · C6 side chain · neutral form

Verification

Every fact on this entry was checked against its primary sources on 20 October 2026.

Wikipedia (English)

Tetrahydrocannabihexol (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

References

  1. Linciano P. et al., identification of cannabidihexol and Δ9-tetrahydrocannabihexol in the FM2 variety (Δ9-THCH about 7 µg/g, not isolated), Sci Rep 2020, 10:22019 (new tab)PMID 33328530
  2. Janssens L. K. et al., intrinsic CB1 activity of hemp-derived and semi-synthetic cannabinoids (β-arrestin 2 recruitment), Arch Toxicol 2024, 98:2619-2630 (new tab)PMID 38735004
  3. Shirakura S. et al., behavioural safety margins of emerging cannabinoids in mice (THC, THCH, THCV, HHC, HHCH, HHCP), Forensic Toxicol 2026 (new tab)PMID 42734683
  4. James K. M. et al., in vitro metabolism (human liver microsomes) of Δ9-THCB, Δ9-THCH and Δ9-THCP, J Anal Toxicol 2026, 50:bkag045 (new tab)PMID 42286420
  5. Tanaka R., Kikura-Hanajiri R., identification of Δ8- and Δ9-THC analogues with alkyl chains of varying length in oils sold online, Yakugaku Zasshi 2024, 144:823-837 (new tab)PMID 39085059
  6. Muir L. S. et al., LC-MS-MS analysis of THC isomers, analogues, homologues and metabolites in blood and urine, J Anal Toxicol 2025, 49:322-331 (new tab)PMID 40098275
  7. ANSM, consolidated list of substances classified as narcotics (26/06/2026): benzo[c]chromene class (annex IV) and parahexyl (annex III) (new tab)
  8. ANSM, decision of 22/05/2024 amending the list of substances classified as narcotics (new tab)
  9. PubChem CID 161906: Δ9-tetrahydrocannabihexol (CAS 36482-24-3 according to ChemIDplus and EPA DSSTox) (new tab)

Identifiers

Names

Common name
Tetrahydrocannabihexol
IUPAC name
(6aR,10aR)-3-hexyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol
Other names
Δ9-THCH · THC-H

Identifiers

Formula
C₂₂H₃₂O₂
CAS
36482-24-3
PubChem CID
161906(new tab)
InChIKey
DMJVNNFBMZZLFB-QZTJIDSGSA-N
SMILES
CCCCCCC1=CC(=C2[C@@H]3C=C(CC[C@H]3C(OC2=C1)(C)C)C)O

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.